Welcome to our dedicated page for Lakewood-Amedex Biotherapeutics SEC filings (Ticker: LABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakewood-Amedex Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakewood-Amedex Biotherapeutics's regulatory disclosures and financial reporting.
Lakewood-Amedex Biotherapeutics Inc. is asking stockholders to approve several governance and capital-structure changes at the September 22, 2026 virtual annual meeting. As of the July 30, 2026 record date, 2,369,688 shares of common stock were outstanding, each with one vote.
Key proposals include: electing four directors for one-year terms; amending the articles of incorporation to increase authorized common stock from 12,500,000 to 100,000,000 shares, which would leave about 97,387,493 authorized but unissued; and authorizing the board to implement, at its discretion through September 22, 2027, one or more reverse stock splits up to a cumulative 1‑for‑20 ratio without reducing authorized shares.
The company also seeks to expand its 2020 Equity Incentive Plan from 183,505 to 400,000 shares and to ratify CBIZ CPAs P.C. as independent auditor for 2026, after paying $197,930 in audit fees in 2025. The board unanimously recommends voting in favor of all proposals.
Lakewood-Amedex Biotherapeutics Inc. furnished an investor presentation describing its Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials aimed at drug-resistant infections and antimicrobial resistance. The deck highlights Nu-3, a topically delivered antimicrobial gel in Phase 2-ready development for infected diabetic foot ulcers (iDFU), with supporting preclinical and early clinical data, safety profile, and a U.S.- and internationally focused Phase 2/Phase 3 regulatory strategy.
The presentation also outlines a development pipeline beyond Nu-3, a planned Phase 2a/2b iDFU trial with key 2026 milestones, and an intellectual property estate of 101 patents with protection extending up to 2044, along with details on the competitive landscape and experienced leadership team.
Lakewood-Amedex Biotherapeutics Inc. reports a Schedule 13G filing disclosing that HPW Investments Holding Ltd. beneficially owns 3,435,501 common shares, representing 24.04% of the outstanding common stock.
The filing states the ownership percentage is calculated based on 14,290,892 ordinary shares outstanding as of March 31, 2026. HPW has sole voting and sole dispositive power over the disclosed shares. The filing is signed by Dr. Martin Kleppe on behalf of the reporting person.
Lakewood-Amedex Biotherapeutics Inc. implemented a 1-for-10 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on June 19, 2026. The company said shares will trade on a split-adjusted basis when Nasdaq opens on June 22, 2026 and that fractional shares will be rounded up.
The Certificate of Change also reduces the company’s authorized common shares to 12,500,000 and the company’s Nasdaq symbol remains LABT; the security has a new CUSIP 51255A201.
Lakewood-Amedex Biotherapeutics Inc. adopted a 1-for-10 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on June 19, 2026, with trading on a split-adjusted basis beginning when Nasdaq opens on June 22, 2026. The company will proportionately adjust outstanding equity awards, preferred stock, warrants and plan issuances, and will reduce authorized common shares to 12,500,000 after the reverse split. The company’s Nasdaq symbol remains LABT and a new CUSIP (51255A201) was assigned.
Lakewood-Amedex Biotherapeutics Inc. is implementing a 1-for-10 reverse stock split of its common stock. The change becomes effective at 4:01 p.m. Eastern Time on June 19, 2026, and the shares will begin trading on a split-adjusted basis on Nasdaq on June 22, 2026 under the existing symbol LABT.
Every ten shares of common stock will be exchanged for one share, with any fractional positions rounded up to the next whole share. The company is also proportionately reducing its authorized common stock to 12,500,000 shares and making equitable adjustments to equity awards, preferred stock, warrants and related exercise or conversion prices. The common stock has been assigned a new CUSIP number, 51255A201.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus supplement to its Form S-1 incorporating its Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $(923,291) for the three months ended March 31, 2026 and cash and cash equivalents of $11,709 as of that date.
The balance sheet shows total assets of $196,343 and total liabilities of $3,037,991, with shares outstanding of 6,995,469 as of March 31, 2026. Subsequent events disclosed include a private sale of Series C Convertible Preferred Stock that closed on April 21, 2026 for gross proceeds of approximately $7.5M (net proceeds ~$6.8M), the automatic conversion of various convertible instruments upon the company’s Nasdaq listing on April 23, 2026, and the filing of a registration statement covering 9,375,000 common shares issuable upon conversion of the Series C Preferred.
Lakewood-Amedex Biotherapeutics Inc. registers 9,375,000 shares of common stock on a Form S-1 prospectus supplement to cover shares issuable upon conversion of its Series C Convertible Preferred Stock. The prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Company reported cash and cash equivalents of $11,709 as of March 31, 2026 and a net loss of $923,291 for the three months then ended. The Company completed a private Series C financing that generated gross proceeds of $7.5 million (net proceeds about $6.8 million) in April 2026 and completed its Nasdaq Capital Market listing on April 23, 2026. Management states the net proceeds and debt conversions improve liquidity and are expected to support operations through the fourth quarter of 2026, but notes that substantial doubt about going concern has not been alleviated.
Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $923,291 for the quarter ended March 31, 2026, with no revenue and an accumulated deficit of $54.3 million. Operating expenses rose to $886,750, driven mainly by higher general and administrative costs linked to Nasdaq listing preparation.
Cash and cash equivalents were $11,709 at quarter-end against total liabilities of $3.0 million and a stockholders’ deficit of $2.8 million, leading management to state that substantial doubt exists about the company’s ability to continue as a going concern. After quarter-end, the company completed a $7.5 million Series C Convertible Preferred Stock financing, receiving approximately $6.8 million net, and all Series A and B preferred shares and $1.5 million of convertible notes converted into common stock upon its Nasdaq Capital Market listing. Management believes this funding supports operations through the fourth quarter of 2026 but still anticipates needing additional capital.
Lakewood-Amedex Biotherapeutics Inc. registers 9,647,726 shares of Common Stock for resale, composed of 9,375,000 shares issuable upon conversion of Series C Preferred Stock and 272,726 shares held by RBW Capital Partners LLC.
The prospectus states the company will receive no proceeds from these resales and that sales may occur at fixed, market, negotiated or other prices through underwriters, brokers, agents, or directly by the selling stockholders. The company paid registration expenses; selling stockholders bear selling commissions and transfer taxes.